Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 85
Selected: 0
NCT IDTitle
NCT02103478Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
NCT00113113Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
NCT04466514A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
NCT00005871Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
NCT01627054A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
NCT00506922Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
NCT01752933SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
NCT01183949Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
NCT00144430Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
NCT05456269A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
NCT02608437A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
NCT04637009A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
NCT02197676A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response
NCT00005876Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
NCT00043381Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
NCT00571662Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
NCT00881166Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
NCT04479800Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
NCT05082259ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
NCT06802146Early Intervention in High Risk CCUS
NCT00005877Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
NCT00041990Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00878423Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
NCT01261312SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
NCT00005870Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
NCT00005874Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
NCT00522990Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
NCT00005873Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT01239108Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
NCT03913455Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
NCT00254163Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
NCT00453193Alemtuzumab and Pentostatin In T-cell Neoplasms
NCT06191978A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT03576963Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
NCT02920008Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
NCT03019003Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
NCT01712217A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
NCT04013880ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT02907359Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
NCT03220477Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
NCT03603964Guadecitabine Extension Study
NCT05245682Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
NCT00042016Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT02901899Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT05007873ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
NCT00006047Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
NCT00032773Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
NCT00005875Nitrocamptothecin in Treating Patients With Metastatic Melanoma
NCT04411030A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
NCT00113256Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer